General Information of Drug Off-Target (DOT) (ID: OT35ZKLI)

DOT Name Small proline-rich protein 2G (SPRR2G)
Synonyms SPR-2G
Gene Name SPRR2G
UniProt ID
SPR2G_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF14820
Sequence
MSYQQQQCKQPCQPPPVCPTPKCPEPCPPPKCPEPYLPPPCPPEHCPPPPCQDKCPPVQP
YPPCQQKYPPKSK
Function
Cross-linked envelope protein of keratinocytes. It is a keratinocyte protein that first appears in the cell cytosol, but ultimately becomes cross-linked to membrane proteins by transglutaminase. All that results in the formation of an insoluble envelope beneath the plasma membrane.
Reactome Pathway
Formation of the cornified envelope (R-HSA-6809371 )

Molecular Interaction Atlas (MIA) of This DOT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
3 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Tretinoin DM49DUI Approved Tretinoin decreases the expression of Small proline-rich protein 2G (SPRR2G). [1]
Hydroquinone DM6AVR4 Approved Hydroquinone increases the expression of Small proline-rich protein 2G (SPRR2G). [1]
Sodium lauryl sulfate DMLJ634 Approved Sodium lauryl sulfate increases the expression of Small proline-rich protein 2G (SPRR2G). [1]
------------------------------------------------------------------------------------
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene affects the methylation of Small proline-rich protein 2G (SPRR2G). [2]
------------------------------------------------------------------------------------

References

1 Retinoic acid and hydroquinone induce inverse expression patterns on cornified envelope-associated proteins: implication in skin irritation. J Dermatol Sci. 2014 Nov;76(2):112-9. doi: 10.1016/j.jdermsci.2014.08.003. Epub 2014 Aug 26.
2 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.